Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1638 1684
This examiner grants 73% of resolved cases
Thomas Russe Amick has resolved 104 cases in Art Unit 1633 within Tech Center 1600. The allowance rate is 73.1%, but the median days to allowance is 1431. This suggests that while success is likely, it takes a significant amount of time to reach a grant. The 1431-day median pendency is a critical factor for applicants to consider when planning their patent strategy.
The interview lift is 30.4%, which is substantial and indicates that interviews are a highly effective tool for this examiner. Given the long 1431-day median pendency, an interview might be a key tactic to resolve issues and potentially move the 73.1% allowance path forward. With 104 resolved cases, the data shows that direct engagement can be a decisive factor in prosecution. Practitioners should use the 30.4% lift to their advantage when navigating the examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18005936 | A CHEMICAL COCKTAIL DRIVING EXPANSION OF MYOGENIC STEM CELLS | Final Rejection | The Regents of the University of California |
| 18417617 | COMPOSITIONS AND METHODS FOR SPATIAL AND TEMPORAL CONTROL OF NEUROTROPHIC GROWTH FACTOR EXPRESSION | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18578381 | DIFFERENTIAL CXCR4 EXPRESSION ON HEMATOPOIETIC PROGENITOR CELLS VERSUS STEM CELLS DIRECTS HOMING AND LONG-TERM ENGRAFTMENT | Non-Final OA | CHILDREN'S HOSPITAL MEDICAL CENTER |
| 18624860 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17831638 | CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF | Non-Final OA | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy